Gynecology Drugs Market Report 2026

The gynecology drugs market size has grown strongly in recent years. It will grow from $45.06 billion in 2025 to $47.52 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to increasing prevalence of gynecological disorders, rising awareness of women’s health, expansion of hospital networks, availability of generic gynecology drugs, adoption of conventional hormonal therapies.

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $58.79 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to advancement in personalized medicine, growth in telemedicine adoption, increased investment in reproductive health research, development of minimally invasive drug delivery systems, expansion of online pharmacy channels. Major trends in the forecast period include personalized gynecology treatments, telemedicine & remote consultations, minimally invasive drug delivery, growth in fertility and reproductive health therapies, rising awareness of women’s health issues.

The increasing number of women diagnosed with ovarian cancer is expected to drive growth in the global gynecological drugs market. Ovarian cancer is a type of cancer that originates in the ovaries, part of the female reproductive system. Gynecological drugs play a vital role in managing ovarian cancer by providing targeted and effective treatments, improving survival rates, and enhancing patients’ quality of life. For example, in February 2023, according to the National Center for Biotechnology Information, a US-based government agency, the global incidence of ovarian cancer is projected to reach 434,184 new cases, with an estimated 293,039 deaths by 2040. This rising incidence is expected to boost demand for gynecological drugs during the forecast period.

Leading companies in the gynecological drug market are focusing on developing innovative therapies, such as hormone replacement therapy (HRT), to gain a competitive advantage. Hormone replacement therapy involves the administration of hormones to relieve symptoms associated with menopause - such as hot flashes, night sweats, mood swings, and vaginal dryness - thereby improving overall quality of life. For instance, in April 2023, the Department of Health and Social Care, a UK-based government administration, in collaboration with NHS England and the NHS Business Services Authority, launched a new Hormone Replacement Therapy prescription prepayment certificate (PPC). This PPC enables women in England to access HRT for just £19.3 per year (approximately $24.5 USD), significantly reducing the financial burden of managing menopause symptoms.

In June 2025, Medicus Pharma Ltd., a US-based pharmaceutical company, acquired Antev Limited Ltd. for an undisclosed amount. Through this acquisition, Medicus Pharma Ltd. aims to expand its product portfolio, strengthen its presence in specialty pharmaceuticals, enhance operational capabilities, and drive growth across its therapeutic segments. Antev Limited Ltd. is a UK-based clinical-stage biotechnology company specializing in gynecological drugs.

Major companies operating in the gynecology drugs market are Pfizer Inc., Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Ferring Pharmaceuticals, Lupin Pharmaceuticals, Organon & Co., Allergan plc, Gedeon Richter, Besins Healthcare, Theramex, Amgen Inc., Agile Therapeutics, Sanofi S.A., Novartis AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca Plc, Cipla Limited, Kissei Pharmaceutical, Shionogi, Mylan N.V., Bristol‑Myers Squibb Company, Endo International PLC, Apothecus Pharmaceutical Corp., Ani Pharmaceuticals, Medicines360, Blairex Laboratories.

North America was the largest region in the gynecology drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the gynecology drugs market by increasing the cost of imported active pharmaceutical ingredients and specialized medical devices used in drug delivery. This has particularly impacted hospital pharmacies and online pharmacies in regions like North America and Europe, which rely on international suppliers. Some subsegments, such as hormonal therapies and fertility drugs, face higher production costs due to these tariffs. However, tariffs have also encouraged local manufacturing initiatives and investments in domestic supply chains, potentially improving regional self-reliance and long-term cost efficiency.

The gynecology drugs market research report is one of a series of new reports that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gynecology drugs pertain to a branch of medicine that deals with the treatment of disorders of the female reproductive system, including care during pregnancy and childbirth. These drugs are used to manage gynecological conditions affecting the uterus, ovaries, and related structures.

The main types of therapeutics in gynecology drugs are hormonal therapy and non-hormonal therapy. Hormonal therapy involves adding, blocking, or removing hormones to slow or stop the growth of cancer cells that rely on hormones to grow. Non-hormonal therapy includes the use of anti-infective and anti-inflammatory agents, lubricants, moisturizers, antidepressants, gabapentin, clonidine, and others. Gynecology drugs are applied in the treatment of gynecological cancers, menopausal disorders, polycystic ovary syndrome, contraception, and other conditions, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.